2024 World Conference on Lung Cancer (WCLC) - Posters-P2.10B.01 Exploratory Analyses of Tusamitamab Ravtansine vs Docetaxel in Previously Treated Non-squamous NSCLC Patients: CARMEN-LC03

P2.10B.01 Exploratory Analyses of Tusamitamab Ravtansine vs Docetaxel in Previously Treated Non-squamous NSCLC Patients: CARMEN-LC03

Back to course

Pdf Summary

The study "Exploratory Analyses of Tusamitamab Ravtansine versus Docetaxel in Previously Treated Patients with Non-Squamous NSCLC: CARMEN-LC03" investigates the efficacy of tusamitamab ravtansine (tusa rav) compared to docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) who have previously undergone treatment with platinum-based chemotherapy and immunotherapy. This Phase 3, open-label, randomized multicenter trial specifically targeted patients whose tumors exhibited high levels of CEACAM5 expression, a marker present in up to 25% of non-squamous NSCLC cases.<br /><br />The primary objective of the trial was to assess progression-free survival (PFS) and overall survival (OS) between the two treatments. Although the primary analysis indicated no significant improvement in PFS with tusa rav, a trend towards enhanced overall survival was observed, along with a favorable safety profile and patient-related outcomes for tusa rav recipients.<br /><br />Further exploratory analyses were conducted to assess outcomes based on CEACAM5 expression levels and patients without actionable genomic alterations (AGAs) and those without prior taxane exposure. Results suggest that in these specific patient subgroups, tusa rav demonstrated potential benefits. For patients with no AGAs and no previous taxane exposure, tusa rav showed a reduced risk of death compared to docetaxel (hazard ratio [HR] 0.71). Additionally, higher CEACAM5 expression was linked to improved median PFS and OS, with patients exhibiting 90% CEACAM5 expression experiencing a 35% reduction in death risk with tusa rav relative to docetaxel.<br /><br />These findings highlight the potential of CEACAM5-directed therapy in select non-squamous NSCLC patients and propose a prognostic significance of CEACAM5 expression. Further research is recommended to validate these findings. The study was funded by Sanofi, and acknowledgments extended to the participants and their families.

Asset Subtitle

Byoung Chul Cho

Meta Tag

Speaker Byoung Chul Cho

Topic Metastatic NSCLC – Cytotoxic Therapy

Keywords

Tusamitamab Ravtansine

Docetaxel

Non-Squamous NSCLC

CEACAM5 Expression

Progression-Free Survival

Overall Survival

Phase 3 Trial

Platinum-based Chemotherapy

Immunotherapy

Sanofi